nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3B—eye—glaucoma	0.00619	0.221	CbGeAlD
Lithium—GSK3B—connective tissue—glaucoma	0.00596	0.213	CbGeAlD
Lithium—GSK3A—eye—glaucoma	0.00538	0.192	CbGeAlD
Lithium—GSK3A—retina—glaucoma	0.00533	0.19	CbGeAlD
Lithium—GSK3A—connective tissue—glaucoma	0.00519	0.185	CbGeAlD
Lithium—Oedema—Brimonidine—glaucoma	0.000799	0.00142	CcSEcCtD
Lithium—Headache—Carbachol—glaucoma	0.000799	0.00142	CcSEcCtD
Lithium—Weight decreased—Betaxolol—glaucoma	0.000798	0.00142	CcSEcCtD
Lithium—Arthralgia—Dorzolamide—glaucoma	0.000796	0.00141	CcSEcCtD
Lithium—Hyperglycaemia—Betaxolol—glaucoma	0.000795	0.00141	CcSEcCtD
Lithium—Dyspepsia—Bimatoprost—glaucoma	0.000794	0.00141	CcSEcCtD
Lithium—Arthralgia—Travoprost—glaucoma	0.000793	0.00141	CcSEcCtD
Lithium—Syncope—Pilocarpine—glaucoma	0.000792	0.00141	CcSEcCtD
Lithium—Nausea—Carteolol—glaucoma	0.000789	0.0014	CcSEcCtD
Lithium—Headache—Levobunolol—glaucoma	0.000786	0.0014	CcSEcCtD
Lithium—Discomfort—Dorzolamide—glaucoma	0.000786	0.0014	CcSEcCtD
Lithium—Shock—Brimonidine—glaucoma	0.000786	0.00139	CcSEcCtD
Lithium—Discomfort—Travoprost—glaucoma	0.000783	0.00139	CcSEcCtD
Lithium—Arthralgia—Brinzolamide—glaucoma	0.000783	0.00139	CcSEcCtD
Lithium—Dry mouth—Dorzolamide—glaucoma	0.000778	0.00138	CcSEcCtD
Lithium—Loss of consciousness—Pilocarpine—glaucoma	0.000776	0.00138	CcSEcCtD
Lithium—Nausea—Diclofenamide—glaucoma	0.000776	0.00138	CcSEcCtD
Lithium—Dry mouth—Travoprost—glaucoma	0.000775	0.00138	CcSEcCtD
Lithium—Discomfort—Brinzolamide—glaucoma	0.000773	0.00137	CcSEcCtD
Lithium—Dizziness—Latanoprost—glaucoma	0.00077	0.00137	CcSEcCtD
Lithium—Confusional state—Dorzolamide—glaucoma	0.000769	0.00137	CcSEcCtD
Lithium—Feeling abnormal—Apraclonidine—glaucoma	0.000767	0.00136	CcSEcCtD
Lithium—Dry mouth—Brinzolamide—glaucoma	0.000765	0.00136	CcSEcCtD
Lithium—Vomiting—Methazolamide—glaucoma	0.000765	0.00136	CcSEcCtD
Lithium—Oedema—Dorzolamide—glaucoma	0.000763	0.00135	CcSEcCtD
Lithium—Gastrointestinal pain—Apraclonidine—glaucoma	0.000761	0.00135	CcSEcCtD
Lithium—Oedema—Travoprost—glaucoma	0.00076	0.00135	CcSEcCtD
Lithium—Rash—Methazolamide—glaucoma	0.000758	0.00135	CcSEcCtD
Lithium—Dermatitis—Methazolamide—glaucoma	0.000758	0.00134	CcSEcCtD
Lithium—Nausea—Carbachol—glaucoma	0.000757	0.00134	CcSEcCtD
Lithium—Tinnitus—Clonidine—glaucoma	0.000756	0.00134	CcSEcCtD
Lithium—Headache—Methazolamide—glaucoma	0.000753	0.00134	CcSEcCtD
Lithium—Arthralgia—Pilocarpine—glaucoma	0.000752	0.00133	CcSEcCtD
Lithium—Shock—Dorzolamide—glaucoma	0.000751	0.00133	CcSEcCtD
Lithium—Hypotension—Brimonidine—glaucoma	0.000747	0.00132	CcSEcCtD
Lithium—Nausea—Levobunolol—glaucoma	0.000746	0.00132	CcSEcCtD
Lithium—Discomfort—Pilocarpine—glaucoma	0.000743	0.00132	CcSEcCtD
Lithium—Somnolence—Acetazolamide—glaucoma	0.00074	0.00131	CcSEcCtD
Lithium—Abdominal pain—Apraclonidine—glaucoma	0.000736	0.00131	CcSEcCtD
Lithium—Rash—Latanoprost—glaucoma	0.000734	0.0013	CcSEcCtD
Lithium—Dermatitis—Latanoprost—glaucoma	0.000733	0.0013	CcSEcCtD
Lithium—Dyspepsia—Acetazolamide—glaucoma	0.000733	0.0013	CcSEcCtD
Lithium—Headache—Latanoprost—glaucoma	0.000729	0.00129	CcSEcCtD
Lithium—Musculoskeletal discomfort—Brimonidine—glaucoma	0.000728	0.00129	CcSEcCtD
Lithium—Anorexia—Dorzolamide—glaucoma	0.000727	0.00129	CcSEcCtD
Lithium—Confusional state—Pilocarpine—glaucoma	0.000727	0.00129	CcSEcCtD
Lithium—Arrhythmia—Clonidine—glaucoma	0.000724	0.00128	CcSEcCtD
Lithium—Decreased appetite—Acetazolamide—glaucoma	0.000724	0.00128	CcSEcCtD
Lithium—Oedema—Pilocarpine—glaucoma	0.000721	0.00128	CcSEcCtD
Lithium—Bradycardia—Betaxolol—glaucoma	0.000718	0.00127	CcSEcCtD
Lithium—Fatigue—Acetazolamide—glaucoma	0.000718	0.00127	CcSEcCtD
Lithium—Alopecia—Clonidine—glaucoma	0.000716	0.00127	CcSEcCtD
Lithium—Nausea—Methazolamide—glaucoma	0.000714	0.00127	CcSEcCtD
Lithium—Hypotension—Dorzolamide—glaucoma	0.000713	0.00127	CcSEcCtD
Lithium—Somnolence—Brimonidine—glaucoma	0.00071	0.00126	CcSEcCtD
Lithium—Hypotension—Travoprost—glaucoma	0.00071	0.00126	CcSEcCtD
Lithium—Shock—Pilocarpine—glaucoma	0.000709	0.00126	CcSEcCtD
Lithium—Dyspepsia—Brimonidine—glaucoma	0.000703	0.00125	CcSEcCtD
Lithium—Hallucination—Betaxolol—glaucoma	0.000702	0.00125	CcSEcCtD
Lithium—Hypotension—Brinzolamide—glaucoma	0.000701	0.00124	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.000695	0.00123	CcSEcCtD
Lithium—Musculoskeletal discomfort—Travoprost—glaucoma	0.000692	0.00123	CcSEcCtD
Lithium—Fatigue—Brimonidine—glaucoma	0.000689	0.00122	CcSEcCtD
Lithium—Anorexia—Pilocarpine—glaucoma	0.000687	0.00122	CcSEcCtD
Lithium—Feeling abnormal—Acetazolamide—glaucoma	0.000686	0.00122	CcSEcCtD
Lithium—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.000683	0.00121	CcSEcCtD
Lithium—Somnolence—Dorzolamide—glaucoma	0.000678	0.0012	CcSEcCtD
Lithium—Hypotension—Pilocarpine—glaucoma	0.000674	0.0012	CcSEcCtD
Lithium—Dyspepsia—Dorzolamide—glaucoma	0.000672	0.00119	CcSEcCtD
Lithium—Dyspepsia—Travoprost—glaucoma	0.000669	0.00119	CcSEcCtD
Lithium—Asthenia—Apraclonidine—glaucoma	0.000668	0.00118	CcSEcCtD
Lithium—Somnolence—Brinzolamide—glaucoma	0.000667	0.00118	CcSEcCtD
Lithium—Vision blurred—Clonidine—glaucoma	0.000665	0.00118	CcSEcCtD
Lithium—GSK3A—Signaling by PDGF—BAD—glaucoma	0.000663	0.00162	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—NCK2—glaucoma	0.000663	0.00162	CbGpPWpGaD
Lithium—Decreased appetite—Dorzolamide—glaucoma	0.000663	0.00118	CcSEcCtD
Lithium—Erectile dysfunction—Timolol—glaucoma	0.000663	0.00118	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—NTRK1—glaucoma	0.000663	0.00162	CbGpPWpGaD
Lithium—Tremor—Clonidine—glaucoma	0.000661	0.00117	CcSEcCtD
Lithium—Dyspepsia—Brinzolamide—glaucoma	0.00066	0.00117	CcSEcCtD
Lithium—Body temperature increased—Acetazolamide—glaucoma	0.000658	0.00117	CcSEcCtD
Lithium—Fatigue—Dorzolamide—glaucoma	0.000658	0.00117	CcSEcCtD
Lithium—Tinnitus—Betaxolol—glaucoma	0.000658	0.00117	CcSEcCtD
Lithium—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.000657	0.00117	CcSEcCtD
Lithium—Fatigue—Travoprost—glaucoma	0.000655	0.00116	CcSEcCtD
Lithium—Decreased appetite—Brinzolamide—glaucoma	0.000652	0.00116	CcSEcCtD
Lithium—Weight decreased—Timolol—glaucoma	0.000652	0.00116	CcSEcCtD
Lithium—GSK3B—Innate Immune System—TXNIP—glaucoma	0.000651	0.00159	CbGpPWpGaD
Lithium—Hyperglycaemia—Timolol—glaucoma	0.00065	0.00115	CcSEcCtD
Lithium—Agitation—Clonidine—glaucoma	0.000648	0.00115	CcSEcCtD
Lithium—Asthenia—Bimatoprost—glaucoma	0.000647	0.00115	CcSEcCtD
Lithium—Fatigue—Brinzolamide—glaucoma	0.000647	0.00115	CcSEcCtD
Lithium—IMPA1—Metabolism—GSTT1—glaucoma	0.000646	0.00158	CbGpPWpGaD
Lithium—Angioedema—Clonidine—glaucoma	0.000645	0.00114	CcSEcCtD
Lithium—Somnolence—Pilocarpine—glaucoma	0.000641	0.00114	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	0.000638	0.00156	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TBK1—glaucoma	0.000638	0.00156	CbGpPWpGaD
Lithium—Diarrhoea—Apraclonidine—glaucoma	0.000637	0.00113	CcSEcCtD
Lithium—Dyspepsia—Pilocarpine—glaucoma	0.000635	0.00113	CcSEcCtD
Lithium—GSK3B—Cardiac Hypertrophic Response—TNF—glaucoma	0.000634	0.00155	CbGpPWpGaD
Lithium—Syncope—Clonidine—glaucoma	0.000633	0.00112	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—LRP12—glaucoma	0.000631	0.00155	CbGpPWpGaD
Lithium—Arrhythmia—Betaxolol—glaucoma	0.00063	0.00112	CcSEcCtD
Lithium—Feeling abnormal—Dorzolamide—glaucoma	0.000629	0.00112	CcSEcCtD
Lithium—GSK3A—B Cell Activation—BAD—glaucoma	0.000628	0.00154	CbGpPWpGaD
Lithium—Decreased appetite—Pilocarpine—glaucoma	0.000627	0.00111	CcSEcCtD
Lithium—Feeling abnormal—Travoprost—glaucoma	0.000626	0.00111	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—NTRK2—glaucoma	0.000625	0.00153	CbGpPWpGaD
Lithium—Gastrointestinal pain—Dorzolamide—glaucoma	0.000624	0.00111	CcSEcCtD
Lithium—Alopecia—Betaxolol—glaucoma	0.000623	0.00111	CcSEcCtD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—CDKN1B—glaucoma	0.000622	0.00152	CbGpPWpGaD
Lithium—Gastrointestinal pain—Travoprost—glaucoma	0.000621	0.0011	CcSEcCtD
Lithium—Loss of consciousness—Clonidine—glaucoma	0.00062	0.0011	CcSEcCtD
Lithium—Feeling abnormal—Brinzolamide—glaucoma	0.000618	0.0011	CcSEcCtD
Lithium—Dizziness—Apraclonidine—glaucoma	0.000615	0.00109	CcSEcCtD
Lithium—GSK3B—Cell Cycle—CDKN2A—glaucoma	0.000613	0.0015	CbGpPWpGaD
Lithium—GSK3A—Immune System—CTSA—glaucoma	0.000609	0.00149	CbGpPWpGaD
Lithium—Abdominal pain—Dorzolamide—glaucoma	0.000603	0.00107	CcSEcCtD
Lithium—Body temperature increased—Dorzolamide—glaucoma	0.000603	0.00107	CcSEcCtD
Lithium—Dysgeusia—Betaxolol—glaucoma	0.000601	0.00107	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—BAD—glaucoma	0.000601	0.00147	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—BAD—glaucoma	0.000601	0.00147	CbGpPWpGaD
Lithium—Arthralgia—Clonidine—glaucoma	0.000601	0.00107	CcSEcCtD
Lithium—Abdominal pain—Travoprost—glaucoma	0.000601	0.00107	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—CDKN2A—glaucoma	0.000599	0.00147	CbGpPWpGaD
Lithium—Asthenia—Acetazolamide—glaucoma	0.000597	0.00106	CcSEcCtD
Lithium—Dizziness—Bimatoprost—glaucoma	0.000597	0.00106	CcSEcCtD
Lithium—Feeling abnormal—Pilocarpine—glaucoma	0.000594	0.00105	CcSEcCtD
Lithium—Discomfort—Clonidine—glaucoma	0.000593	0.00105	CcSEcCtD
Lithium—Vomiting—Apraclonidine—glaucoma	0.000592	0.00105	CcSEcCtD
Lithium—GSK3B—BDNF signaling pathway—BAD—glaucoma	0.000591	0.00145	CbGpPWpGaD
Lithium—Gastrointestinal pain—Pilocarpine—glaucoma	0.00059	0.00105	CcSEcCtD
Lithium—Dry mouth—Clonidine—glaucoma	0.000587	0.00104	CcSEcCtD
Lithium—Bradycardia—Timolol—glaucoma	0.000587	0.00104	CcSEcCtD
Lithium—Dermatitis—Apraclonidine—glaucoma	0.000586	0.00104	CcSEcCtD
Lithium—GSK3B—Copper homeostasis—TP53—glaucoma	0.000584	0.00143	CbGpPWpGaD
Lithium—Headache—Apraclonidine—glaucoma	0.000583	0.00103	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—CDKN2A—glaucoma	0.000581	0.00142	CbGpPWpGaD
Lithium—GSK3A—Disease—FGFR1OP—glaucoma	0.000581	0.00142	CbGpPWpGaD
Lithium—GSK3A—Disease—HEYL—glaucoma	0.000581	0.00142	CbGpPWpGaD
Lithium—Confusional state—Clonidine—glaucoma	0.000581	0.00103	CcSEcCtD
Lithium—Vision blurred—Betaxolol—glaucoma	0.000579	0.00103	CcSEcCtD
Lithium—IMPA2—Metabolism—CYP1B1—glaucoma	0.000577	0.00141	CbGpPWpGaD
Lithium—IMPA2—Metabolism—ABCA1—glaucoma	0.000577	0.00141	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—C1QB—glaucoma	0.000577	0.00141	CbGpPWpGaD
Lithium—Oedema—Clonidine—glaucoma	0.000576	0.00102	CcSEcCtD
Lithium—Tremor—Betaxolol—glaucoma	0.000575	0.00102	CcSEcCtD
Lithium—GSK3B—Downstream signaling of activated FGFR—BAD—glaucoma	0.000575	0.00141	CbGpPWpGaD
Lithium—Hallucination—Timolol—glaucoma	0.000574	0.00102	CcSEcCtD
Lithium—Asthenia—Brimonidine—glaucoma	0.000573	0.00102	CcSEcCtD
Lithium—Body temperature increased—Pilocarpine—glaucoma	0.00057	0.00101	CcSEcCtD
Lithium—Abdominal pain—Pilocarpine—glaucoma	0.00057	0.00101	CcSEcCtD
Lithium—Diarrhoea—Acetazolamide—glaucoma	0.00057	0.00101	CcSEcCtD
Lithium—Rash—Bimatoprost—glaucoma	0.000569	0.00101	CcSEcCtD
Lithium—Dermatitis—Bimatoprost—glaucoma	0.000568	0.00101	CcSEcCtD
Lithium—GSK3B—ErbB Signaling Pathway—TP53—glaucoma	0.000567	0.00139	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—CDKN1B—glaucoma	0.000567	0.00139	CbGpPWpGaD
Lithium—Shock—Clonidine—glaucoma	0.000566	0.00101	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—BAD—glaucoma	0.000566	0.00139	CbGpPWpGaD
Lithium—Headache—Bimatoprost—glaucoma	0.000565	0.001	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—NGF—glaucoma	0.00056	0.00137	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—CDKN1B—glaucoma	0.00056	0.00137	CbGpPWpGaD
Lithium—Nausea—Apraclonidine—glaucoma	0.000553	0.000981	CcSEcCtD
Lithium—Vertigo—Betaxolol—glaucoma	0.000552	0.000979	CcSEcCtD
Lithium—Syncope—Betaxolol—glaucoma	0.000551	0.000977	CcSEcCtD
Lithium—Dizziness—Acetazolamide—glaucoma	0.000551	0.000977	CcSEcCtD
Lithium—Anorexia—Clonidine—glaucoma	0.000549	0.000974	CcSEcCtD
Lithium—Asthenia—Dorzolamide—glaucoma	0.000547	0.000971	CcSEcCtD
Lithium—GSK3B—PI3K/AKT activation—CDKN1B—glaucoma	0.000547	0.00134	CbGpPWpGaD
Lithium—Asthenia—Travoprost—glaucoma	0.000545	0.000967	CcSEcCtD
Lithium—GSK3B—Cell Cycle—CDKN1B—glaucoma	0.000543	0.00133	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—CDKN1B—glaucoma	0.000543	0.00133	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—CDKN1B—glaucoma	0.000542	0.00133	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—BAD—glaucoma	0.000541	0.00132	CbGpPWpGaD
Lithium—Loss of consciousness—Betaxolol—glaucoma	0.00054	0.000958	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—NGF—glaucoma	0.000538	0.00132	CbGpPWpGaD
Lithium—Asthenia—Brinzolamide—glaucoma	0.000538	0.000955	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR—BAD—glaucoma	0.000538	0.00132	CbGpPWpGaD
Lithium—Hypotension—Clonidine—glaucoma	0.000538	0.000955	CcSEcCtD
Lithium—Tinnitus—Timolol—glaucoma	0.000537	0.000954	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—NGFR—glaucoma	0.000536	0.00131	CbGpPWpGaD
Lithium—Nausea—Bimatoprost—glaucoma	0.000536	0.000951	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB2—BAD—glaucoma	0.000535	0.00131	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—CDKN1B—glaucoma	0.000534	0.00131	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—BAD—glaucoma	0.000533	0.0013	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—CDKN1B—glaucoma	0.00053	0.0013	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—CDKN1B—glaucoma	0.00053	0.0013	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—FAS—glaucoma	0.000529	0.0013	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—SOD1—glaucoma	0.000529	0.0013	CbGpPWpGaD
Lithium—Vomiting—Acetazolamide—glaucoma	0.000529	0.000939	CcSEcCtD
Lithium—Dizziness—Brimonidine—glaucoma	0.000528	0.000937	CcSEcCtD
Lithium—GSK3B—p53 pathway—TP53—glaucoma	0.000528	0.00129	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—BAD—glaucoma	0.000525	0.00129	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—MMP9—glaucoma	0.000525	0.00129	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Clonidine—glaucoma	0.000525	0.000931	CcSEcCtD
Lithium—Arthralgia—Betaxolol—glaucoma	0.000523	0.000928	CcSEcCtD
Lithium—Diarrhoea—Dorzolamide—glaucoma	0.000522	0.000926	CcSEcCtD
Lithium—Headache—Acetazolamide—glaucoma	0.000522	0.000925	CcSEcCtD
Lithium—Diarrhoea—Travoprost—glaucoma	0.00052	0.000922	CcSEcCtD
Lithium—Asthenia—Pilocarpine—glaucoma	0.000517	0.000918	CcSEcCtD
Lithium—Discomfort—Betaxolol—glaucoma	0.000517	0.000917	CcSEcCtD
Lithium—Arrhythmia—Timolol—glaucoma	0.000515	0.000914	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—CDKN1B—glaucoma	0.000515	0.00126	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CYP1B1—glaucoma	0.000514	0.00126	CbGpPWpGaD
Lithium—IMPA1—Metabolism—ABCA1—glaucoma	0.000514	0.00126	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TXN—glaucoma	0.000514	0.00126	CbGpPWpGaD
Lithium—Diarrhoea—Brinzolamide—glaucoma	0.000513	0.000911	CcSEcCtD
Lithium—GSK3A—Immune System—TXNIP—glaucoma	0.000513	0.00126	CbGpPWpGaD
Lithium—Somnolence—Clonidine—glaucoma	0.000512	0.000908	CcSEcCtD
Lithium—Dry mouth—Betaxolol—glaucoma	0.000511	0.000907	CcSEcCtD
Lithium—GSK3A—Downstream signal transduction—CDKN1B—glaucoma	0.00051	0.00125	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—NTRK1—glaucoma	0.00051	0.00125	CbGpPWpGaD
Lithium—Alopecia—Timolol—glaucoma	0.000509	0.000904	CcSEcCtD
Lithium—GSK3A—Signaling by FGFR—CDKN1B—glaucoma	0.000507	0.00124	CbGpPWpGaD
Lithium—Confusional state—Betaxolol—glaucoma	0.000505	0.000897	CcSEcCtD
Lithium—GSK3A—Signaling by ERBB2—CDKN1B—glaucoma	0.000505	0.00124	CbGpPWpGaD
Lithium—Dizziness—Dorzolamide—glaucoma	0.000505	0.000895	CcSEcCtD
Lithium—Rash—Brimonidine—glaucoma	0.000504	0.000894	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—CAV1—glaucoma	0.000504	0.00123	CbGpPWpGaD
Lithium—Dermatitis—Brimonidine—glaucoma	0.000503	0.000893	CcSEcCtD
Lithium—GSK3A—Immune System—TBK1—glaucoma	0.000503	0.00123	CbGpPWpGaD
Lithium—Dizziness—Travoprost—glaucoma	0.000502	0.000891	CcSEcCtD
Lithium—GSK3A—DAP12 signaling—CDKN1B—glaucoma	0.000502	0.00123	CbGpPWpGaD
Lithium—Oedema—Betaxolol—glaucoma	0.000501	0.000889	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—BAD—glaucoma	0.000501	0.00123	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—BAD—glaucoma	0.000501	0.00123	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—BAD—glaucoma	0.000501	0.00123	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDKN2B—glaucoma	0.000501	0.00123	CbGpPWpGaD
Lithium—Headache—Brimonidine—glaucoma	0.000501	0.000888	CcSEcCtD
Lithium—Decreased appetite—Clonidine—glaucoma	0.000501	0.000888	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR—BAD—glaucoma	0.000497	0.00122	CbGpPWpGaD
Lithium—Fatigue—Clonidine—glaucoma	0.000496	0.000881	CcSEcCtD
Lithium—Dizziness—Brinzolamide—glaucoma	0.000496	0.00088	CcSEcCtD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—CDKN1B—glaucoma	0.000495	0.00121	CbGpPWpGaD
Lithium—Nausea—Acetazolamide—glaucoma	0.000494	0.000877	CcSEcCtD
Lithium—Diarrhoea—Pilocarpine—glaucoma	0.000493	0.000875	CcSEcCtD
Lithium—Shock—Betaxolol—glaucoma	0.000493	0.000875	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—BAD—glaucoma	0.000492	0.00121	CbGpPWpGaD
Lithium—Dysgeusia—Timolol—glaucoma	0.000491	0.000872	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—BAD—glaucoma	0.00049	0.0012	CbGpPWpGaD
Lithium—Vomiting—Dorzolamide—glaucoma	0.000485	0.000861	CcSEcCtD
Lithium—Rash—Dorzolamide—glaucoma	0.000481	0.000854	CcSEcCtD
Lithium—Dermatitis—Dorzolamide—glaucoma	0.000481	0.000853	CcSEcCtD
Lithium—GSK3B—Focal Adhesion—FN1—glaucoma	0.000479	0.00117	CbGpPWpGaD
Lithium—Rash—Travoprost—glaucoma	0.000479	0.00085	CcSEcCtD
Lithium—Dermatitis—Travoprost—glaucoma	0.000479	0.000849	CcSEcCtD
Lithium—Headache—Dorzolamide—glaucoma	0.000478	0.000848	CcSEcCtD
Lithium—Anorexia—Betaxolol—glaucoma	0.000478	0.000848	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—IL1A—glaucoma	0.000478	0.00117	CbGpPWpGaD
Lithium—Vomiting—Brinzolamide—glaucoma	0.000477	0.000846	CcSEcCtD
Lithium—Dizziness—Pilocarpine—glaucoma	0.000477	0.000846	CcSEcCtD
Lithium—Headache—Travoprost—glaucoma	0.000476	0.000844	CcSEcCtD
Lithium—Nausea—Brimonidine—glaucoma	0.000475	0.000842	CcSEcCtD
Lithium—Feeling abnormal—Clonidine—glaucoma	0.000474	0.000842	CcSEcCtD
Lithium—GSK3B—Alzheimers Disease—TNF—glaucoma	0.000474	0.00116	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—BAD—glaucoma	0.000474	0.00116	CbGpPWpGaD
Lithium—Rash—Brinzolamide—glaucoma	0.000473	0.000839	CcSEcCtD
Lithium—Vision blurred—Timolol—glaucoma	0.000473	0.000839	CcSEcCtD
Lithium—Dermatitis—Brinzolamide—glaucoma	0.000473	0.000838	CcSEcCtD
Lithium—GSK3A—DAP12 interactions—CDKN1B—glaucoma	0.000472	0.00116	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—CDKN1B—glaucoma	0.000472	0.00116	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—CDKN1B—glaucoma	0.000472	0.00116	CbGpPWpGaD
Lithium—Gastrointestinal pain—Clonidine—glaucoma	0.000471	0.000835	CcSEcCtD
Lithium—Headache—Brinzolamide—glaucoma	0.00047	0.000834	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	0.000469	0.00115	CbGpPWpGaD
Lithium—Hypotension—Betaxolol—glaucoma	0.000468	0.000831	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR—CDKN1B—glaucoma	0.000468	0.00115	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LRP12—glaucoma	0.000466	0.00114	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—CDKN1B—glaucoma	0.000464	0.00114	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—BAD—glaucoma	0.000464	0.00114	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—BAD—glaucoma	0.000462	0.00113	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—CDKN1B—glaucoma	0.000462	0.00113	CbGpPWpGaD
Lithium—IMPA2—Metabolism—GSTM1—glaucoma	0.000461	0.00113	CbGpPWpGaD
Lithium—Angioedema—Timolol—glaucoma	0.000458	0.000813	CcSEcCtD
Lithium—Vomiting—Pilocarpine—glaucoma	0.000458	0.000813	CcSEcCtD
Lithium—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000457	0.00081	CcSEcCtD
Lithium—Abdominal pain—Clonidine—glaucoma	0.000455	0.000808	CcSEcCtD
Lithium—Body temperature increased—Clonidine—glaucoma	0.000455	0.000808	CcSEcCtD
Lithium—GSK3A—Immune System—C1QB—glaucoma	0.000455	0.00111	CbGpPWpGaD
Lithium—Rash—Pilocarpine—glaucoma	0.000455	0.000807	CcSEcCtD
Lithium—Dermatitis—Pilocarpine—glaucoma	0.000454	0.000806	CcSEcCtD
Lithium—Nausea—Dorzolamide—glaucoma	0.000453	0.000804	CcSEcCtD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TNF—glaucoma	0.000452	0.00111	CbGpPWpGaD
Lithium—Headache—Pilocarpine—glaucoma	0.000452	0.000801	CcSEcCtD
Lithium—Nausea—Travoprost—glaucoma	0.000451	0.000801	CcSEcCtD
Lithium—GSK3B—TCF dependent signaling in response to WNT—CAV1—glaucoma	0.000451	0.0011	CbGpPWpGaD
Lithium—Vertigo—Timolol—glaucoma	0.000451	0.0008	CcSEcCtD
Lithium—GSK3B—Immune System—CTSA—glaucoma	0.00045	0.0011	CbGpPWpGaD
Lithium—Syncope—Timolol—glaucoma	0.00045	0.000798	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—PAX6—glaucoma	0.000449	0.0011	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—VEGFA—glaucoma	0.000446	0.00109	CbGpPWpGaD
Lithium—Nausea—Brinzolamide—glaucoma	0.000446	0.000791	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	0.000445	0.00109	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—BAD—glaucoma	0.000444	0.00109	CbGpPWpGaD
Lithium—Dyspepsia—Betaxolol—glaucoma	0.000441	0.000783	CcSEcCtD
Lithium—Loss of consciousness—Timolol—glaucoma	0.000441	0.000782	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—OPN4—glaucoma	0.000438	0.00107	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—CDKN1B—glaucoma	0.000437	0.00107	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—CAV1—glaucoma	0.000437	0.00107	CbGpPWpGaD
Lithium—Decreased appetite—Betaxolol—glaucoma	0.000436	0.000773	CcSEcCtD
Lithium—Fatigue—Betaxolol—glaucoma	0.000432	0.000767	CcSEcCtD
Lithium—GSK3B—Developmental Biology—PAX6—glaucoma	0.00043	0.00105	CbGpPWpGaD
Lithium—GSK3B—Disease—FGFR1OP—glaucoma	0.000429	0.00105	CbGpPWpGaD
Lithium—GSK3B—Disease—HEYL—glaucoma	0.000429	0.00105	CbGpPWpGaD
Lithium—Nausea—Pilocarpine—glaucoma	0.000428	0.00076	CcSEcCtD
Lithium—Arthralgia—Timolol—glaucoma	0.000427	0.000758	CcSEcCtD
Lithium—Discomfort—Timolol—glaucoma	0.000422	0.000749	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—CDKN1B—glaucoma	0.000419	0.00103	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—CDKN1B—glaucoma	0.000418	0.00102	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TP53—glaucoma	0.000418	0.00102	CbGpPWpGaD
Lithium—Dry mouth—Timolol—glaucoma	0.000418	0.000741	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—NGF—glaucoma	0.000414	0.00101	CbGpPWpGaD
Lithium—Asthenia—Clonidine—glaucoma	0.000413	0.000733	CcSEcCtD
Lithium—Feeling abnormal—Betaxolol—glaucoma	0.000413	0.000733	CcSEcCtD
Lithium—Confusional state—Timolol—glaucoma	0.000413	0.000733	CcSEcCtD
Lithium—IMPA1—Metabolism—GSTM1—glaucoma	0.000411	0.00101	CbGpPWpGaD
Lithium—Oedema—Timolol—glaucoma	0.00041	0.000727	CcSEcCtD
Lithium—IMPA2—Metabolism—MTHFR—glaucoma	0.000408	0.000999	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HEYL—glaucoma	0.000407	0.000996	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—glaucoma	0.000406	0.000994	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—CAV1—glaucoma	0.000406	0.000993	CbGpPWpGaD
Lithium—GSK3A—Immune System—TXN—glaucoma	0.000405	0.000993	CbGpPWpGaD
Lithium—Shock—Timolol—glaucoma	0.000403	0.000715	CcSEcCtD
Lithium—GSK3B—Downstream signaling of activated FGFR—CDKN1B—glaucoma	0.000401	0.000981	CbGpPWpGaD
Lithium—Body temperature increased—Betaxolol—glaucoma	0.000396	0.000703	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB4—CDKN1B—glaucoma	0.000394	0.000966	CbGpPWpGaD
Lithium—Diarrhoea—Clonidine—glaucoma	0.000394	0.000699	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—PTGFR—glaucoma	0.000394	0.000965	CbGpPWpGaD
Lithium—Anorexia—Timolol—glaucoma	0.00039	0.000693	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—MMP9—glaucoma	0.000388	0.00095	CbGpPWpGaD
Lithium—Hypotension—Timolol—glaucoma	0.000383	0.000679	CcSEcCtD
Lithium—Dizziness—Clonidine—glaucoma	0.000381	0.000676	CcSEcCtD
Lithium—IMPA2—Metabolism—APOE—glaucoma	0.00038	0.00093	CbGpPWpGaD
Lithium—GSK3B—Immune System—TXNIP—glaucoma	0.000379	0.000928	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—CDKN1B—glaucoma	0.000377	0.000922	CbGpPWpGaD
Lithium—IMPA2—Metabolism—CAV1—glaucoma	0.000376	0.000921	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—CDKN1B—glaucoma	0.000375	0.000918	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Timolol—glaucoma	0.000373	0.000662	CcSEcCtD
Lithium—GSK3B—Signaling by ERBB2—CDKN1B—glaucoma	0.000373	0.000913	CbGpPWpGaD
Lithium—GSK3B—Immune System—TBK1—glaucoma	0.000372	0.00091	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—CDKN1B—glaucoma	0.000371	0.000909	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	0.00037	0.000905	CbGpPWpGaD
Lithium—Vomiting—Clonidine—glaucoma	0.000366	0.00065	CcSEcCtD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—CDKN1B—glaucoma	0.000366	0.000896	CbGpPWpGaD
Lithium—Somnolence—Timolol—glaucoma	0.000364	0.000646	CcSEcCtD
Lithium—IMPA1—Metabolism—MTHFR—glaucoma	0.000363	0.00089	CbGpPWpGaD
Lithium—Rash—Clonidine—glaucoma	0.000363	0.000644	CcSEcCtD
Lithium—Dermatitis—Clonidine—glaucoma	0.000363	0.000644	CcSEcCtD
Lithium—GSK3A—Disease—HDAC9—glaucoma	0.000363	0.000888	CbGpPWpGaD
Lithium—Headache—Clonidine—glaucoma	0.000361	0.00064	CcSEcCtD
Lithium—Dyspepsia—Timolol—glaucoma	0.00036	0.00064	CcSEcCtD
Lithium—Asthenia—Betaxolol—glaucoma	0.00036	0.000638	CcSEcCtD
Lithium—Decreased appetite—Timolol—glaucoma	0.000356	0.000632	CcSEcCtD
Lithium—Fatigue—Timolol—glaucoma	0.000353	0.000626	CcSEcCtD
Lithium—GSK3B—Signaling by FGFR in disease—CDKN1B—glaucoma	0.000349	0.000855	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—CDKN1B—glaucoma	0.000349	0.000855	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—CDKN1B—glaucoma	0.000349	0.000855	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—CDKN1B—glaucoma	0.000346	0.000847	CbGpPWpGaD
Lithium—Diarrhoea—Betaxolol—glaucoma	0.000343	0.000609	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—CDKN1B—glaucoma	0.000343	0.00084	CbGpPWpGaD
Lithium—Nausea—Clonidine—glaucoma	0.000342	0.000607	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—BAD—glaucoma	0.000341	0.000836	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—CDKN1B—glaucoma	0.000341	0.000836	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—TP53—glaucoma	0.000341	0.000835	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—glaucoma	0.000341	0.000835	CbGpPWpGaD
Lithium—IMPA1—Metabolism—APOE—glaucoma	0.000338	0.000829	CbGpPWpGaD
Lithium—Feeling abnormal—Timolol—glaucoma	0.000337	0.000599	CcSEcCtD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—glaucoma	0.000337	0.000826	CbGpPWpGaD
Lithium—GSK3B—Immune System—C1QB—glaucoma	0.000336	0.000823	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CAV1—glaucoma	0.000335	0.000821	CbGpPWpGaD
Lithium—Gastrointestinal pain—Timolol—glaucoma	0.000335	0.000594	CcSEcCtD
Lithium—GSK3B—Signaling by Wnt—CAV1—glaucoma	0.000334	0.000819	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—glaucoma	0.000333	0.000816	CbGpPWpGaD
Lithium—Dizziness—Betaxolol—glaucoma	0.000331	0.000588	CcSEcCtD
Lithium—Abdominal pain—Timolol—glaucoma	0.000324	0.000574	CcSEcCtD
Lithium—Body temperature increased—Timolol—glaucoma	0.000324	0.000574	CcSEcCtD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—glaucoma	0.000323	0.000792	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—OPN4—glaucoma	0.000323	0.000792	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—CDKN1B—glaucoma	0.000323	0.000791	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—CDKN1B—glaucoma	0.000322	0.000788	CbGpPWpGaD
Lithium—Vomiting—Betaxolol—glaucoma	0.000319	0.000566	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	0.000317	0.000776	CbGpPWpGaD
Lithium—Rash—Betaxolol—glaucoma	0.000316	0.000561	CcSEcCtD
Lithium—Dermatitis—Betaxolol—glaucoma	0.000316	0.00056	CcSEcCtD
Lithium—Headache—Betaxolol—glaucoma	0.000314	0.000557	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—CDKN1B—glaucoma	0.000309	0.000757	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RPTOR—glaucoma	0.000308	0.000755	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—C3—glaucoma	0.000304	0.000744	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HEYL—glaucoma	0.000301	0.000736	CbGpPWpGaD
Lithium—GSK3B—Immune System—TXN—glaucoma	0.0003	0.000734	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NCK2—glaucoma	0.000299	0.000731	CbGpPWpGaD
Lithium—Nausea—Betaxolol—glaucoma	0.000298	0.000528	CcSEcCtD
Lithium—Asthenia—Timolol—glaucoma	0.000294	0.000521	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—C3—glaucoma	0.000292	0.000714	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PTGFR—glaucoma	0.000291	0.000713	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—BCL2L1—glaucoma	0.000291	0.000712	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDKN2A—glaucoma	0.000286	0.000701	CbGpPWpGaD
Lithium—IMPA2—Metabolism—NOS3—glaucoma	0.000284	0.000697	CbGpPWpGaD
Lithium—Diarrhoea—Timolol—glaucoma	0.00028	0.000497	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	0.000279	0.000684	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—VEGFA—glaucoma	0.000274	0.000672	CbGpPWpGaD
Lithium—Dizziness—Timolol—glaucoma	0.000271	0.00048	CcSEcCtD
Lithium—GSK3B—Disease—HDAC9—glaucoma	0.000268	0.000656	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP2—glaucoma	0.000265	0.00065	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—BAD—glaucoma	0.000264	0.000645	CbGpPWpGaD
Lithium—Vomiting—Timolol—glaucoma	0.00026	0.000462	CcSEcCtD
Lithium—IMPA2—Metabolism—PTGS2—glaucoma	0.00026	0.000637	CbGpPWpGaD
Lithium—Rash—Timolol—glaucoma	0.000258	0.000458	CcSEcCtD
Lithium—Dermatitis—Timolol—glaucoma	0.000258	0.000458	CcSEcCtD
Lithium—Headache—Timolol—glaucoma	0.000257	0.000455	CcSEcCtD
Lithium—GSK3A—Metabolism of proteins—MMP1—glaucoma	0.000255	0.000626	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HDAC9—glaucoma	0.000254	0.000622	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CDKN1B—glaucoma	0.000254	0.000621	CbGpPWpGaD
Lithium—IMPA1—Metabolism—NOS3—glaucoma	0.000253	0.000621	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—BAD—glaucoma	0.000253	0.00062	CbGpPWpGaD
Lithium—Nausea—Timolol—glaucoma	0.000243	0.000432	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—CDKN1B—glaucoma	0.000238	0.000582	CbGpPWpGaD
Lithium—IMPA1—Metabolism—PTGS2—glaucoma	0.000232	0.000568	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—RPTOR—glaucoma	0.000228	0.000558	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—C3—glaucoma	0.000225	0.00055	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NCK2—glaucoma	0.000221	0.00054	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—C3—glaucoma	0.000216	0.000528	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—BCL2L1—glaucoma	0.000215	0.000526	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—VEGFA—glaucoma	0.000211	0.000516	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL1A—glaucoma	0.000201	0.000493	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP9—glaucoma	0.000199	0.000488	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SMO—glaucoma	0.000199	0.000486	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—glaucoma	0.000198	0.000485	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—MMP2—glaucoma	0.000198	0.000484	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN2B—glaucoma	0.000195	0.000477	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—BAD—glaucoma	0.000195	0.000477	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP2—glaucoma	0.000189	0.000463	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HDAC9—glaucoma	0.000188	0.000459	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—BAD—glaucoma	0.000187	0.000458	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CDKN1B—glaucoma	0.000184	0.00045	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NTRK2—glaucoma	0.000182	0.000445	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—glaucoma	0.000179	0.000438	CbGpPWpGaD
Lithium—GSK3A—Immune System—C3—glaucoma	0.000177	0.000433	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—CDKN1B—glaucoma	0.000176	0.000432	CbGpPWpGaD
Lithium—GSK3A—Immune System—BCL2L1—glaucoma	0.000169	0.000415	CbGpPWpGaD
Lithium—GSK3A—Disease—MTHFR—glaucoma	0.000163	0.0004	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—glaucoma	0.000159	0.00039	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NGFR—glaucoma	0.000156	0.000382	CbGpPWpGaD
Lithium—GSK3A—Immune System—BAD—glaucoma	0.000154	0.000376	CbGpPWpGaD
Lithium—GSK3A—Disease—APOE—glaucoma	0.000152	0.000372	CbGpPWpGaD
Lithium—GSK3A—Disease—CAV1—glaucoma	0.000151	0.000369	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL1A—glaucoma	0.000149	0.000364	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NTRK1—glaucoma	0.000148	0.000363	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SMO—glaucoma	0.000147	0.000359	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN2B—glaucoma	0.000144	0.000353	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—glaucoma	0.000142	0.000348	CbGpPWpGaD
Lithium—GSK3A—Disease—BAD—glaucoma	0.000142	0.000347	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN2B—glaucoma	0.000136	0.000334	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CDKN1B—glaucoma	0.000136	0.000332	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NTRK2—glaucoma	0.000134	0.000329	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EDN1—glaucoma	0.000131	0.000321	CbGpPWpGaD
Lithium—GSK3B—Immune System—C3—glaucoma	0.000131	0.00032	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CDKN1B—glaucoma	0.00013	0.000319	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—glaucoma	0.000128	0.000313	CbGpPWpGaD
Lithium—GSK3B—Immune System—BCL2L1—glaucoma	0.000125	0.000307	CbGpPWpGaD
Lithium—GSK3B—Disease—MTHFR—glaucoma	0.000121	0.000296	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NGF—glaucoma	0.00012	0.000295	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NGFR—glaucoma	0.000115	0.000282	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—C3—glaucoma	0.000114	0.00028	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS3—glaucoma	0.000114	0.000279	CbGpPWpGaD
Lithium—GSK3B—Immune System—BAD—glaucoma	0.000113	0.000278	CbGpPWpGaD
Lithium—GSK3B—Disease—APOE—glaucoma	0.000112	0.000275	CbGpPWpGaD
Lithium—GSK3B—Disease—CAV1—glaucoma	0.000111	0.000273	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—glaucoma	0.000109	0.000268	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NTRK1—glaucoma	0.000109	0.000268	CbGpPWpGaD
Lithium—GSK3A—Immune System—CDKN1B—glaucoma	0.000107	0.000262	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—APOE—glaucoma	0.000107	0.000261	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CAV1—glaucoma	0.000106	0.000258	CbGpPWpGaD
Lithium—GSK3B—Disease—BAD—glaucoma	0.000105	0.000256	CbGpPWpGaD
Lithium—GSK3A—Disease—PTGS2—glaucoma	0.000104	0.000255	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN2B—glaucoma	0.000101	0.000247	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—FN1—glaucoma	0.0001	0.000246	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—BAD—glaucoma	9.93e-05	0.000243	CbGpPWpGaD
Lithium—GSK3A—Disease—CDKN1B—glaucoma	9.87e-05	0.000242	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EDN1—glaucoma	9.68e-05	0.000237	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NGF—glaucoma	8.89e-05	0.000218	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—C3—glaucoma	8.45e-05	0.000207	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS3—glaucoma	8.42e-05	0.000206	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOS3—glaucoma	7.98e-05	0.000195	CbGpPWpGaD
Lithium—GSK3B—Immune System—CDKN1B—glaucoma	7.9e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—APOE—glaucoma	7.87e-05	0.000193	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CAV1—glaucoma	7.8e-05	0.000191	CbGpPWpGaD
Lithium—GSK3B—Disease—PTGS2—glaucoma	7.7e-05	0.000189	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—FN1—glaucoma	7.42e-05	0.000182	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—BAD—glaucoma	7.33e-05	0.00018	CbGpPWpGaD
Lithium—GSK3B—Disease—CDKN1B—glaucoma	7.29e-05	0.000179	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CDKN1B—glaucoma	6.91e-05	0.000169	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—glaucoma	6.4e-05	0.000157	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOS3—glaucoma	5.9e-05	0.000144	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—glaucoma	5.75e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CDKN1B—glaucoma	5.11e-05	0.000125	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—glaucoma	4.73e-05	0.000116	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—glaucoma	4.34e-05	0.000106	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—glaucoma	4.25e-05	0.000104	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—glaucoma	3.21e-05	7.86e-05	CbGpPWpGaD
